Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.44 |
| ▸ | CNR2 | P34972 | 8/20 | 0.44 |
| ▸ | CFD | P00746 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14411452 | 1.00 | PDE10A (0.44) | PDE10ACNR2CFDEPHX2KLKB1 | |
| SCHEMBL5454568 | 1.00 | PDE10A (0.44) | PDE10ACNR2CFDEPHX2KLKB1 | |
| SCHEMBL14412141 | 0.94 | PDE10A (0.45) | PDE10ACNR2CFDEPHX2KLKB1 | |
| SCHEMBL14412142 | 0.93 | PDE10A (0.45) | PDE10ACNR2CFDEPHX2KLKB1 | |
| SCHEMBL14411453 | 0.93 | PDE10A (0.44) | PDE10ACNR2CFDEPHX2MAPT | |
| SCHEMBL14411448 | 0.92 | PDE10A (0.43) | PDE10ACNR2CFDEPHX2KLKB1 | |
| SCHEMBL5447879 | 0.92 | PDE10A (0.43) | PDE10ACNR2CFDEPHX2KLKB1 | |
| SCHEMBL5447878 | 0.92 | PDE10A (0.43) | PDE10ACNR2CFDEPHX2KLKB1 | |
| SCHEMBL14412101 | 0.89 | PDE10A (0.44) | PDE10ACNR2CFDEPHX2KLKB1 | |
| SCHEMBL14411417 | 0.89 | CNR2 (0.44) | PDE10ACNR2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | GIPR, GHSR, GHRHR | PDE10A 514/4885CNR2 106/4885CFD 3529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.